MCOLN2 and central nervous system cancer: Silencing of TRPML2 mRNA in T98 and U251 increases the sensitivity of glioma cells to the DOX cytotoxic effects (siGLO vs. siTRPML2 T98 cells, IC50 = 21 vs. 9.7 μM; siGLO vs. siTRPML2 U251 cells, IC50 = 3.0 vs. 1.0 μM), suggesting that TRPML2 can contribute to DOX resistance in GBM cells (Figure 5).